✦ LIBER ✦

Paclitaxel plus cisplatin and lonidamine showed `good activity' in advanced ovarian cancer,

Book ID: 120867447
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2001
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200112850-00024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paclitaxel, cisplatin and lonidamine in

Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study

✍ M. De Lena; V. Lorusso; A. Latorre; G. Fanizza; G. Gargano; L. Caporusso; M. Gui 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Update on paclitaxel plus cisplatin in a

Update on paclitaxel plus cisplatin in advanced ovarian cancer

✍ Schäffer, J.; Floege, J.; Koch, K. M. 📂 Article 📅 1998 🏛 Adis International Limited (now part of Wolters Kl ⚖ 166 KB

Cisplatin plus ifosfamide shows activity

Cisplatin plus ifosfamide shows activity in ovarian cancer

📂 Article 📅 1999 🏛 Adis International Limited (now part of Wolters Kl ⚖ 265 KB

Paclitaxel plus cisplatin active in adva

Paclitaxel plus cisplatin active in advanced oesophageal cancer

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Infusional cisplatin plus cyclophosphami

Infusional cisplatin plus cyclophosphamide in advanced ovarian cancer

✍ Jacob Lokich; Thomas Zipoli; Robert Green 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 399 KB

Enhancement of cisplatin activity by lon

Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells

✍ Rosella Silvestrini; Nadia Zaffaroni; Raffaella Villa; Linda Orlandi; Aurora Cos 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 524 KB

The ability of lonidamine, an energolytic derivative of indazolecarboxylic acid, to modulate the cytotoxicity of cisplatin was investigated in human ovarian-cancer cell lines sensitive (A2780) or with experimentally induced resistance (A2780/cp8) to the alkylating agent. A 24-hr post-incubation with